Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions

Source: Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy
In this podcast episode, listen to Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on managing patients with T-cell lymphoma using biomarker-driven therapies.
Francine Foss, MD
Steven M. Horwitz, MD
Barbara Pro, MD
Released: January 31, 2022

In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:

  • Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCL
  • Managing relapsed mycosis fungoides after allogeneic SCT
  • Experience with ALK inhibition in ALCL with central nervous system metastases
  • Managing refractory pruritus in CTCL
  • Role of PI3K inhibitors in frontline and relapsed/refractory PTCL
  • When to consider SCT in CTCL cycling through monotherapies

Information on this Educational Activity

Faculty

Steven M. Horwitz, MD

Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from ADCT Therapeutics, Affimed, Aileron, Angimmune, BeiGene, Corvus, Forty-Seven, Infinity/Verastem, Innate Pharma, Kura, Kyowa Hakka Kirin, Merck, Millennium/Takeda, Miragen, Mundipharma, Portola, Seattle Genetics, and Syros and funds for research support from ADCT Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Versatem, Kyowa Hakka Kirin, Millennium/Takeda, Seattle Genetics, and Trillium.
Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Francine Foss, MD, has disclosed that she has received consulting fees from Mallinkrodt and Miragen and fees for non-CME/CE services from Seattle Genetics and Spectrum.
Barbara Pro, MD

Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Chicago, Illinois

Barbara Pro, MD, has disclosed that she has received funds for research support from Celgene, Seattle Genetics, and Takeda and consulting fees from Celgene, Kyowa, Portola, Seattle Genetics, and Takeda.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Kyowa Kirin, Inc.
Seagen Inc.
Takeda Oncology

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings